Search: onr:"swepub:oai:DiVA.org:liu-104694" >
Epigenetic inactiva...
-
Wang, LQUniversity of Hong Kong, China
(author)
Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
- Article/chapterEnglish2014
Publisher, publication year, extent ...
-
2014-02-22
-
BioMed Central,2014
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-104694
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-104694URI
-
https://doi.org/10.1186/1479-5876-12-52DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
BACKGROUND:TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might correlate with miR-203 or miR-124-1 methylation in CLL.METHODS:miR-34b/c, miR-34a and DAPK1 methylation was studied in 11 normal controls, 7 CLL cell lines, and 78 diagnostic CLL samples by methylation-specific polymerase chain reaction. MEC-1 cells were treated with 5-Aza-2'-deoxycytidine for reversal of methylation-associated miRNA silencing. Tumor suppressor properties of miR-34b were demonstrated by over-expression of precursor miR-34b in MEC-1 cells.RESULTS:miR-34b/c promoter was unmethylated in normal controls, but completely methylated in 4 CLL cell lines. miR-34b/c expression inversely correlated with miR-34b/c methylation. Different MSP statuses of miR-34b/c, including complete methylation and complete unmethylation, were verified by quantitative bisulfite pyrosequencing. 5-Aza-2'-deoxycytidine treatment resulted in promoter demethylation and miR-34b re-expression in MEC1 cells. Moreover, over-expression of miR-34b resulted in inhibition of cellular proliferation and increased cell death. In primary CLL samples, miR-34a, miR-34b/c and DAPK1 methylation was detected in 2.6%, 17.9% and 34.6% of patients at diagnosis respectively. Furthermore, 39.7%, 3.8% and 2.6% patients had methylation of one, two or all three genes respectively. Overall, 46.2% patients had methylation of at least one of these three genes. Besides, miR-34b/c methylation was associated with methylation of miR-34a (P = 0.03) and miR-203 (P = 0.012) in CLL.CONCLUSIONS:Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Kwong, YLUniversity of Hong Kong, China
(author)
-
Wong, KFQueen Elizabeth Hospital, Hong Kong, China
(author)
-
Kho, CSPamela Youde Nethersole Hospital, Hong Kong, China
(author)
-
Jin, DYUniversity of Hong Kong, China
(author)
-
Tse, EUniversity of Hong Kong, China
(author)
-
Rosén, AndersLinköpings universitet,Avdelningen för cellbiologi,Hälsouniversitetet(Swepub:liu)andro72
(author)
-
Chim, CSUniversity of Hong Kong, China
(author)
-
University of Hong Kong, ChinaQueen Elizabeth Hospital, Hong Kong, China
(creator_code:org_t)
Related titles
-
In:Journal of Translational Medicine: BioMed Central12:521479-5876
Internet link
Find in a library
To the university's database